Comparing Stereotactic Body Radiotherapy with Three-Dimensional Conformal Radiotherapy for Patients with Unresectable or Recurrent Hepatocellular Carcinoma

Jang-Chun Lin, Yee Min Jen, Wen Yen Huang, Chang Min Chen, Hsing-Luog Chao, Chun Shun Lin, Yu Fu Su, Kuen Tze Lin, Chao Yueh Fan, Wei-Yuan Nien, Miao-Jung Lin

Research output: Contribution to journalArticle

Abstract

Purpose: To compare stereotactic body radiotherapy (SBRT) with three-dimensional conformal radiotherapy (3D-CRT) for improving hepatocellullar carcimona (HCC) patient survival rates.Material and Method: Forty-one patients with unresectable or recurrent HCC were divided into one group of 20 patients who received SBRT, and another group of 21 patients who received 3D-CRT. They were treated in the Radiation Oncology Department of the Tri-Service General Hospital from March 2007 to March 2009. The median follow-up time for all patients was 12 months (range 2 to 36 months). Overall survival was the primary end point.Results: For the 3D-CRT and SBRT patient groups, the median survival (MS) was 11 months and 16 months with the 1-year overall survival (OS) of 42.9% and 70.0%, respectively. In the univariate analysis, CyberKnife SBRT (p= 0.019), non-advanced Okuda stage (p= 0.002), serum albumin higher than 3.5g /dl (p= 0.008), and total bilirubin lower than 2.0 mg/dL (p= 0.042) were associated with significantly better OS. Further statistical analyses showed that those patients in Child-Pugh class A who received SBRT had better OS than those who received 3D-CRT (p= 0.047). Multivariate analyses revealed that Okuda stage (p= 0.006). Child-Pugh class (p= 0.042) and technique of RT (p= 0.029) were significant prognostic factors for OS.Conclusions: This study showed that patients who received SBRT had significantly better OS than those who received 3D-CRT. SBRT has the advantage of short overall treatment times compared to 3D-CRT. Our results also suggest that SBRT could be considered first in patients with Child-Pugh class A. Further study is required to define the effects of administered radiation dose and fractionation.
Original languageEnglish
Pages (from-to)105-117
Number of pages13
Journal放射治療與腫瘤學
Volume19
Issue number2
DOIs
Publication statusPublished - Jun 1 2012
Externally publishedYes

Fingerprint

Conformal Radiotherapy
Radiosurgery
Hepatocellular Carcinoma
Survival
Dose Fractionation
Radiation Oncology
Radiation Effects
Bilirubin
Serum Albumin
General Hospitals
Multivariate Analysis
Survival Rate

Keywords

  • HCC
  • Stereotactic body radiotherapy
  • Three-Dimensional conlormal radiotherapy

Cite this

Comparing Stereotactic Body Radiotherapy with Three-Dimensional Conformal Radiotherapy for Patients with Unresectable or Recurrent Hepatocellular Carcinoma. / Lin, Jang-Chun; Jen, Yee Min; Huang, Wen Yen; Chen, Chang Min; Chao, Hsing-Luog; Lin, Chun Shun; Su, Yu Fu; Lin, Kuen Tze; Fan, Chao Yueh; Nien, Wei-Yuan; Lin, Miao-Jung.

In: 放射治療與腫瘤學, Vol. 19, No. 2, 01.06.2012, p. 105-117.

Research output: Contribution to journalArticle

Lin, Jang-Chun ; Jen, Yee Min ; Huang, Wen Yen ; Chen, Chang Min ; Chao, Hsing-Luog ; Lin, Chun Shun ; Su, Yu Fu ; Lin, Kuen Tze ; Fan, Chao Yueh ; Nien, Wei-Yuan ; Lin, Miao-Jung. / Comparing Stereotactic Body Radiotherapy with Three-Dimensional Conformal Radiotherapy for Patients with Unresectable or Recurrent Hepatocellular Carcinoma. In: 放射治療與腫瘤學. 2012 ; Vol. 19, No. 2. pp. 105-117.
@article{2100d9c3e7084d739f17b1e388ec5087,
title = "Comparing Stereotactic Body Radiotherapy with Three-Dimensional Conformal Radiotherapy for Patients with Unresectable or Recurrent Hepatocellular Carcinoma",
abstract = "Purpose: To compare stereotactic body radiotherapy (SBRT) with three-dimensional conformal radiotherapy (3D-CRT) for improving hepatocellullar carcimona (HCC) patient survival rates.Material and Method: Forty-one patients with unresectable or recurrent HCC were divided into one group of 20 patients who received SBRT, and another group of 21 patients who received 3D-CRT. They were treated in the Radiation Oncology Department of the Tri-Service General Hospital from March 2007 to March 2009. The median follow-up time for all patients was 12 months (range 2 to 36 months). Overall survival was the primary end point.Results: For the 3D-CRT and SBRT patient groups, the median survival (MS) was 11 months and 16 months with the 1-year overall survival (OS) of 42.9{\%} and 70.0{\%}, respectively. In the univariate analysis, CyberKnife SBRT (p= 0.019), non-advanced Okuda stage (p= 0.002), serum albumin higher than 3.5g /dl (p= 0.008), and total bilirubin lower than 2.0 mg/dL (p= 0.042) were associated with significantly better OS. Further statistical analyses showed that those patients in Child-Pugh class A who received SBRT had better OS than those who received 3D-CRT (p= 0.047). Multivariate analyses revealed that Okuda stage (p= 0.006). Child-Pugh class (p= 0.042) and technique of RT (p= 0.029) were significant prognostic factors for OS.Conclusions: This study showed that patients who received SBRT had significantly better OS than those who received 3D-CRT. SBRT has the advantage of short overall treatment times compared to 3D-CRT. Our results also suggest that SBRT could be considered first in patients with Child-Pugh class A. Further study is required to define the effects of administered radiation dose and fractionation.",
keywords = "HCC, Stereotactic body radiotherapy, Three-Dimensional conlormal radiotherapy, 肝癌, 立體定位放射治療, 三度空間順形放射治療",
author = "Jang-Chun Lin and Jen, {Yee Min} and Huang, {Wen Yen} and Chen, {Chang Min} and Hsing-Luog Chao and Lin, {Chun Shun} and Su, {Yu Fu} and Lin, {Kuen Tze} and Fan, {Chao Yueh} and Wei-Yuan Nien and Miao-Jung Lin",
year = "2012",
month = "6",
day = "1",
doi = "http://www.airitilibrary.com/Publication/alDetailedMesh?DocID=1023988x-201206-201208130006-201208130006-105-117",
language = "English",
volume = "19",
pages = "105--117",
journal = "放射治療與腫瘤學",
issn = "1023-988x",
publisher = "台灣放射腫瘤學會",
number = "2",

}

TY - JOUR

T1 - Comparing Stereotactic Body Radiotherapy with Three-Dimensional Conformal Radiotherapy for Patients with Unresectable or Recurrent Hepatocellular Carcinoma

AU - Lin, Jang-Chun

AU - Jen, Yee Min

AU - Huang, Wen Yen

AU - Chen, Chang Min

AU - Chao, Hsing-Luog

AU - Lin, Chun Shun

AU - Su, Yu Fu

AU - Lin, Kuen Tze

AU - Fan, Chao Yueh

AU - Nien, Wei-Yuan

AU - Lin, Miao-Jung

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Purpose: To compare stereotactic body radiotherapy (SBRT) with three-dimensional conformal radiotherapy (3D-CRT) for improving hepatocellullar carcimona (HCC) patient survival rates.Material and Method: Forty-one patients with unresectable or recurrent HCC were divided into one group of 20 patients who received SBRT, and another group of 21 patients who received 3D-CRT. They were treated in the Radiation Oncology Department of the Tri-Service General Hospital from March 2007 to March 2009. The median follow-up time for all patients was 12 months (range 2 to 36 months). Overall survival was the primary end point.Results: For the 3D-CRT and SBRT patient groups, the median survival (MS) was 11 months and 16 months with the 1-year overall survival (OS) of 42.9% and 70.0%, respectively. In the univariate analysis, CyberKnife SBRT (p= 0.019), non-advanced Okuda stage (p= 0.002), serum albumin higher than 3.5g /dl (p= 0.008), and total bilirubin lower than 2.0 mg/dL (p= 0.042) were associated with significantly better OS. Further statistical analyses showed that those patients in Child-Pugh class A who received SBRT had better OS than those who received 3D-CRT (p= 0.047). Multivariate analyses revealed that Okuda stage (p= 0.006). Child-Pugh class (p= 0.042) and technique of RT (p= 0.029) were significant prognostic factors for OS.Conclusions: This study showed that patients who received SBRT had significantly better OS than those who received 3D-CRT. SBRT has the advantage of short overall treatment times compared to 3D-CRT. Our results also suggest that SBRT could be considered first in patients with Child-Pugh class A. Further study is required to define the effects of administered radiation dose and fractionation.

AB - Purpose: To compare stereotactic body radiotherapy (SBRT) with three-dimensional conformal radiotherapy (3D-CRT) for improving hepatocellullar carcimona (HCC) patient survival rates.Material and Method: Forty-one patients with unresectable or recurrent HCC were divided into one group of 20 patients who received SBRT, and another group of 21 patients who received 3D-CRT. They were treated in the Radiation Oncology Department of the Tri-Service General Hospital from March 2007 to March 2009. The median follow-up time for all patients was 12 months (range 2 to 36 months). Overall survival was the primary end point.Results: For the 3D-CRT and SBRT patient groups, the median survival (MS) was 11 months and 16 months with the 1-year overall survival (OS) of 42.9% and 70.0%, respectively. In the univariate analysis, CyberKnife SBRT (p= 0.019), non-advanced Okuda stage (p= 0.002), serum albumin higher than 3.5g /dl (p= 0.008), and total bilirubin lower than 2.0 mg/dL (p= 0.042) were associated with significantly better OS. Further statistical analyses showed that those patients in Child-Pugh class A who received SBRT had better OS than those who received 3D-CRT (p= 0.047). Multivariate analyses revealed that Okuda stage (p= 0.006). Child-Pugh class (p= 0.042) and technique of RT (p= 0.029) were significant prognostic factors for OS.Conclusions: This study showed that patients who received SBRT had significantly better OS than those who received 3D-CRT. SBRT has the advantage of short overall treatment times compared to 3D-CRT. Our results also suggest that SBRT could be considered first in patients with Child-Pugh class A. Further study is required to define the effects of administered radiation dose and fractionation.

KW - HCC

KW - Stereotactic body radiotherapy

KW - Three-Dimensional conlormal radiotherapy

KW - 肝癌

KW - 立體定位放射治療

KW - 三度空間順形放射治療

U2 - http://www.airitilibrary.com/Publication/alDetailedMesh?DocID=1023988x-201206-201208130006-201208130006-105-117

DO - http://www.airitilibrary.com/Publication/alDetailedMesh?DocID=1023988x-201206-201208130006-201208130006-105-117

M3 - Article

VL - 19

SP - 105

EP - 117

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

SN - 1023-988x

IS - 2

ER -